Emergent BioSolutions Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2019 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Emergent BioSolutions Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2019 to Q2 2025.
  • Emergent BioSolutions Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2025 was $4.6M, a 16.4% decline year-over-year.
  • Emergent BioSolutions Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2025 was $12.7M, a 34.5% decline year-over-year.
  • Emergent BioSolutions Inc. annual Share-based Payment Arrangement, Expense for 2024 was $18M, a 22.1% decline from 2023.
  • Emergent BioSolutions Inc. annual Share-based Payment Arrangement, Expense for 2023 was $23.1M, a 48.8% decline from 2022.
  • Emergent BioSolutions Inc. annual Share-based Payment Arrangement, Expense for 2022 was $45.1M, a 6.37% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 $12.7M $4.6M -$900K -16.4% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-07
Q1 2025 $13.6M $1.5M -$4.4M -74.6% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q4 2024 $18M $4.3M +$300K +7.5% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-04
Q3 2024 $17.7M $2.3M -$1.7M -42.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $19.4M $5.5M -$2.8M -33.7% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-07
Q1 2024 $22.2M $5.9M -$900K -13.2% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 $23.1M $4M -$7.7M -65.8% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-04
Q3 2023 $30.8M $4M -$7.2M -64.3% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $38M $8.3M -$4M -32.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $42M $6.8M -$3.1M -31.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $45.1M $11.7M +$1.6M +15.8% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-04
Q3 2022 $43.5M $11.2M +$800K +7.69% Jul 1, 2022 Sep 30, 2022 10-Q 2023-12-11
Q2 2022 $42.7M $12.3M +$900K +7.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $41.8M $9.9M -$600K -5.71% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $42.4M $10.1M -$700K -6.48% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-08
Q3 2021 $43.1M $10.4M +$400K +4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $42.7M $11.4M -$13M -53.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 $55.7M $10.5M +$3.9M +59.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-29
Q4 2020 $51.8M $10.8M Oct 1, 2020 Dec 31, 2020 10-K/A 2023-12-11
Q3 2020 $10M +$3.9M +63.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 $24.4M +$16.3M +201% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-30
Q1 2020 $6.6M Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q3 2019 $6.1M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $8.1M Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.